Hepatitis Monthly

Published by: Kowsar

Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients

Mihajlo Jakovljevic 1 , * , Zeljko Mijailovic 2 , Biljana Popovska Jovicic 2 , Predrag Canovic 2 , Olgica Gajovic 2 , Mirjana Jovanovic 3 , Dejan Petrovic 4 , Olivera Milovanovic 5 and Natasa Djordjevic 1
Authors Information
1 Pharmacology and Toxicology Department, The Faculty of Medical Sciences Kragujevac, University of Kragujevac, Kragujevac, Serbia
2 Infectious Diseases Clinic, University Clinical Center Kragujevac, Kragujevac, Serbia
3 Regional Addiction Disorders Center, Psychiatry Clinic, University Clinical Center Kragujevac, Kragujevac, Serbia
4 Urology and Nephrology Clinic, University Clinical Center Kragujevac, Kragujevac, Serbia
5 Department of Pharmacy The Faculty of Medical Sciences University of Kragujevac, Kragujevac, Serbia
Article information
  • Hepatitis Monthly: June 01, 2013, 13 (6); e6750
  • Published Online: June 19, 2013
  • Article Type: Research Article
  • Received: June 11, 2012
  • Revised: January 31, 2013
  • Accepted: April 15, 2013
  • DOI: 10.5812/hepatmon.6750

To Cite: Jakovljevic M, Mijailovic Z, Popovska Jovicic B, Canovic P, Gajovic O, et al. Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients, Hepat Mon. 2013 ; 13(6):e6750. doi: 10.5812/hepatmon.6750.

Abstract
Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39(4): 1147-71[PubMed]
  • 2. Pecic V, Stankovic-Djordjevic D, Nestorovic M, Radojkovic M, Marjanovic H, Ilic B, et al. Hepatitis C virus-related hepatocellular carcinoma and liver cirrhosis. J Buon. 2011; 16(2): 277-81[PubMed]
  • 3. Chevaliez S, Pawlotsky JM. Hepatitis C virus: virology, diagnosis and management of antiviral therapy. World J Gastroenterol. 2007; 13(17): 2461-6[PubMed]
  • 4. De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature. 2005; 436(7053): 953-60[PubMed]
  • 5. Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C, Payan C, Pivert A, Goudeau A, et al. Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J Gastroenterol. 2007; 13(17): 2416-26[PubMed]
  • 6. Lee CM, Hung CH, Lu SN, Changchien CS. Hepatitis C virus genotypes: clinical relevance and therapeutic implications. Chang Gung Med J. 2008; 31(1): 16-25[PubMed]
  • 7. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev. 2000; 13(2): 223-35[PubMed]
  • 8. Kuljic-Kapulica N, Jovanovic D, Savic D, Ristanovic E, Nozic D, Rajic R. [Therapy of chronic hepatitis C--virologic response monitoring]. Vojnosanit Pregl. 2010; 67(11): 923-7[PubMed]
  • 9. Briggs A, Shiell A. Interferon-alpha in hepatitis C. Dosage, costs and benefits. Pharmacoeconomics. 1996; 10(3): 205-9[PubMed]
  • 10. Garcia de Ancos JL, Roberts JA, Dusheiko GM. An economic evaluation of the costs of alpha-interferon treatment of chronic active hepatitis due to hepatitis B or C virus. J Hepatol. 1990; 11 Suppl 1-8[PubMed]
  • 11. Hartwell D, Jones J, Baxter L, Shepherd J. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess. 2011; 15(17)-210[PubMed]
  • 12. Solomon M, Bonafede M, Pan K, Wilson K, Beam C, Chakravarti P, et al. Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients. Dig Dis Sci. 2011; 56(10): 3024-31[PubMed]
  • 13. Wong JB. Interferon treatment for chronic hepatitis B or C infection: costs and effectiveness. Acta Gastroenterol Belg. 1998; 61(2): 238-42[PubMed]
  • 14. Nikolic P, Jemuovic L, Delic D, Korac M, Boricic I. Treatment of chronic hepatitis C with interferon alpha – our results. Acta Infectologica Yugoslavica. 2000; 5: 1-9
  • 15. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005; 42(4): 962-73[PubMed]
  • 16. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007; 39(2): 175-91[PubMed]
  • 17. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006; 130(4): 1086-97[PubMed]
  • 18. Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O. Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up. J Viral Hepat. 2012; 19(2)-104[PubMed]
  • 19. Jacobs P, Fassbender K. The measurement of indirect costs in the health economics evaluation literature. A review. Int J Technol Assess Health Care. 1998; 14(4): 799-808[PubMed]
  • 20. Matsuura K, Tanaka Y, Hasegawa I, Ohno T, Tokuda H, Kurbanov F, et al. Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients. J Clin Microbiol. 2009; 47(2): 385-9[PubMed]
  • 21. Health statistical yearbook of Republic of Serbia 2010. 2010;
  • 22. Annemans L. Health economics for non-economists: an introduction to the concepts, methods and pitfalls of health economic evaluations. 2008;
  • 23. Gajic-Stevanovic M, Vuksa A, Zivkovic S, Teodorovic N. Cost of primary health care in the Republic of Serbia for the period 2006-2008. Serbian Dental J. 2010; 57: 86-97
  • 24. Gerkens S, Nechelput M, Annemans L, Peraux B, Mouchart M, Beguin C, et al. A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C. J Viral Hepat. 2007; 14(8): 523-36[PubMed]
  • 25. O'Hagan A, Stevens JW, Montmartin J. Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio. Pharmacoeconomics. 2000; 17(4): 339-49[PubMed]
  • 26. Carlsson T, Quist A, Weiland O. Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: comparison between two HCV RNA quantitation methods. J Med Virol. 2008; 80(5): 803-7[PubMed]
  • 27. Marcellin P, Reau N, Ferenci P, Hadziyannis S, Messinger D, Tatsch F, et al. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. J Hepatol. 2012;
  • 28. Romeo JM, Ulrich PP, Busch MP, Vyas GN. Analysis of hepatitis C virus RNA prevalence and surrogate markers of infection among seropositive voluntary blood donors. Hepatology. 1993; 17(2): 188-95[PubMed]
  • 29. Singal AK, Anand BS. Tailoring treatment duration to 12 to 16 weeks in hepatitis C genotype 2 or 3 with rapid virologic response: systematic review and meta-analysis of randomized controlled trials. J Clin Gastroenterol. 2010; 44(8): 583-7[PubMed]
  • 30. Glied S. Mandates and the affordability of health care. Inquiry. 2009; 46(2): 203-14[PubMed]
  • 31. Noble SM, Hollingworth W, Tilling K. Missing data in trial-based cost-effectiveness analysis: the current state of play. Health Econ. 2012; 21(2): 187-200[PubMed]
  • 32. Su J, Brook RA, Kleinman NL, Corey-Lisle P. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology. 2010; 52(2): 436-42[PubMed]
  • 33. Shah NM, Brieger WR, Peters DH. Can interventions improve health services from informal private providers in low and middle-income countries?: a comprehensive review of the literature. Health Policy Plan. 2011; 26(4): 275-87[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments